<DOC>
	<DOCNO>NCT00443508</DOCNO>
	<brief_summary>This study design compare two different strategy aim lessen degree ongoing process allograft injury either remove tacrolimus maintenance immunosuppressive protocol reduce tacrolimus dose . The primary goal ass change renal function 6 12 month conversion use creatinine level calculate creatinine clearance . The study include two group : The study group 30 patient match control group creatinine level similar range .</brief_summary>
	<brief_title>Reduction Discontinuation CNI 's With Conversion Everolimus-Based Immunosuppresion</brief_title>
	<detailed_description>This study design compare two different strategy aim lessen degree ongoing process allograft injury either remove tacrolimus maintenance immunosuppressive protocol reduce tacrolimus dose . The primary goal ass change renal function 6 12 month conversion use creatinine level calculate creatinine clearance . The study include two group : The study group 30 patient match control group creatinine level similar range . Patients undergo follow baseline study : 1 . Doppler ultrasound exclude mechanical vascular problem . 2 . A kidney biopsy define histological change ( degree interstitial fibrosis , tubular glomerular change ) . The biopsy stain also C4D fibrinogenic marker ( TGF-beta , collagen ) . 3 . A 24-hour urine protein excretion creatinine clearance 4 . Echocardiography study 5 . Carotid Ultrasound The following parameter monitor every clinic visit throughout study period : 1 . SMA-12 include creatinine level . 2 . A complete blood count . 3 . Cholesterol , HDL-cholesterol triglyceride level . 4 . Blood pressure measurement ( X2 ) 5 . The number blood pressure medication . 6 . Cholesterol lower medication requirement 7 . Urine protein excretion ( quantitative spot-test ) 8 . Protein amount urine Study end point : The data evaluate base intention treat analysis follow parameter compare two group : 1 . Creatinine level calculate creatinine clearance 2 . Spot urine Cr./protein ratio 3 . 24-hr . protein excretion 4 . Change peak diastolic mean arterial blood pressure 5 . The number dosage blood pressure medication 6 . Cholesterol , HDL triglyceride level 7 . Proportion patient cholesterol lower agent 8 . Number severity biopsy proven acute rejection episodes 9 . Incidence biopsy proven chronic rejection . ( depend per protocol biopsy end study ) 10 . Patient graft survival</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Patients CNI FK &lt; 5 ng/m '' l MPA / Imuran without steroid Renal impairment GFR 30 70 '' l/minute/ Patient sign Informed consent Patient contraindication renal biopsy Women pregnant use contraception Proteinuria &gt; 100 '' g/mmol Creatinine Acute rejection 3 month screen WBC &lt; 2500 , plt &lt; 50,000 , Nephropathy due polyoma virus Patients investigational drug Patients rapamycin Patients HIV systemic infection Inability comply protocol requirement Active history malignancy</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>everolimus</keyword>
	<keyword>renal transplant</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>Certican</keyword>
	<keyword>CHRONIC ALLOGRAFT NEPHROPATHY</keyword>
	<keyword>Renal transplant patient</keyword>
</DOC>